Role of HBsAg Testing in the Management of Patients with Chronic HBV

被引：5
作者：
Hong T.-C. [1 ]
Yang H.-C. [1 ,2 ]
Kao J.-H. [1 ,2 ,3 ]
机构：
[1] Department of Internal Medicine, National Taiwan University Hospital, Taipei
[2] Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University, 1 Chang-Te Street, Taipei
[3] Hepatitis Research Center, National Taiwan University Hospital, Taipei
来源：
Current Hepatology Reports | 2019年 / 18卷 / 3期
关键词：
Antiviral therapy; Chronic hepatitis B; Functional cure; HBsAg quantification; Hepatitis B virus;
D O I：
10.1007/s11901-019-00484-y
中图分类号：
学科分类号：
摘要：
Purpose of Review: HBsAg has been an important serological marker for the diagnosis of hepatitis B virus (HBV) infection. Recently, HBsAg quantification has been utilized to predict the disease activity and the response to antiviral treatment. This review aims to update the clinical utility of HBsAg quantification in the management of chronic hepatitis B (CHB). Recent Findings: HBsAg level varies across different phases of the natural history of CHB, highest in the immune-tolerant phase and lowest in inactive carriers. HBsAg level is useful to stratify the risk of hepatocellular carcinoma in low-viremic patients. HBsAg level also helps predict the HBsAg loss in HBeAg-negative patients. Moreover, baseline level and on-treatment kinetics of HBsAg are associated with the treatment response to pegylated interferon and nucleos(t)ide analogs in both HBeAg-positive and HBeAg-negative patients. Finally, HBsAg level can serve as a therapeutic endpoint marker for evaluating novel curative agents against HBV infection. Summary: HBsAg quantification can help guide the management of CHB. © Springer Science+Business Media, LLC, part of Springer Nature 2019.
引用
收藏
页码：331 / 341
页数：10
相关论文
共 89 条
[1]  
Blumberg B.S., Gerstley B.J., Hungerford D.A., London W.T., Sutnick A.I., A serum antigen (Australia antigen) in Down's syndrome, leukemia, and hepatitis, Ann Intern Med, 66, 5, pp. 924-931, (1967)
[2]  
Kao J.H., Chen D.S., Global control of hepatitis B virus infection, Lancet Infect Dis, 2, 7, pp. 395-403, (2002)
[3]  
Raimondo G., Locarnini S., Pollicino T., Levrero M., Zoulim F., Lok A.S., Update of the statements on biology and clinical impact of occult hepatitis b virus infection, J Hepatol, (2019)
[4]  
Kao J.H., Role of viral factors in the natural course and therapy of chronic hepatitis B, Hepatol Int, 1, 4, pp. 415-430, (2007)
[5]  
Liaw Y.F., Chu C.M., Hepatitis B virus infection, Lancet, 373, 9663, pp. 582-592, (2009)
[6]  
Kao J.H., Chen P.J., Chen D.S., Recent advances in the research of hepatitis B virus-related hepatocellular carcinoma: epidemiologic and molecular biological aspects, Adv Cancer Res, 108, pp. 21-72, (2010)
[7]  
Cornberg M., Wong V.W., Locarnini S., Brunetto M., Janssen H.L.A., Chan H.L., The role of quantitative hepatitis B surface antigen revisited, J Hepatol, 66, 2, pp. 398-411, (2017)
[8]  
Revill Pa, Block C.F.V., Dandri J.M., Gehring M., Guo A.J.H., A global scientific strategy to cure hepatitis B, Lancet Gastroenterol Hepatol, (2019)
[9]  
Seeger C., Mason W.S., Molecular biology of hepatitis B virus infection, Virology, 479-480, pp. 672-686, (2015)
[10]  
Mason W.S., Gill U.S., Litwin S., Zhou Y., Peri S., Pop O., Hong M.L.W., Naik S., Quaglia A., Bertoletti A., Kennedy P.T.F., HBV DNA integration and clonal hepatocyte expansion in chronic hepatitis B patients considered immune tolerant, Gastroenterology, 151, 5, pp. 986-998, (2016)
123456789